PLx Pharm Signs First China Licensing Deal With Lee’s Pharma For GI-safe Aspirin
This article was originally published in PharmAsia News
Lee’s Pharma looks to take on Bayer’s aspirin in China by seeking an Rx indication.
You may also be interested in...
Lee's Pharmaceutical In-Licenses United Therapeutics' Pulmonary Arterial Hypertension Treatment Remodulin In China
SHANGHAI - Hong Kong-based Lee's Pharmaceutical and U.S.-based United Therapeutics signed an agreement for the distribution of United Therapeutics' pulmonary arterial hypertension treatment Remodulin (treprostinil) in China, despite a recent setback for the drug's launch in Europe
HONG KONG - A famous ability to copy, combined with a chronic shortage of innovation, has long defined China's pharmaceutical industry
Shiseido has strategic initiatives planned for its domestic and Chinese businesses and Bare Escentuals in the U.S. following a disappointing fiscal 2012 in which the Toyko-based firm recorded a net loss of $148 million.